Alpha¹ by KaimenConfidential

Kaimen Rigor review

Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.

Hammond J, Yunis C, Fountaine RJ, Luscan G, Burr AM, Zhang W, Wisemandle W, Soares H, Baniecki ML, Hendrick VM, Kalfov V, Pypstra R, Rusnak JM

DOI: 10.1056/NEJMoa2309002
Record issued: 2026-08-16
Engine: 7.39.0
Exported: 2026-09-22

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/5f4a54fe-fb2d-4611-8d20-040c526b6da3 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary endpoint was not met; the observed risk reductions were not statistically significant (29.8% and 35.5% with P=0.17 and P=0.12, respectively). The effect size is not anchored to a clinically meaningful threshold and is not statistically supported.
“In each nirmatrelvir–ritonavir group, the percentage of participants in whom symptomatic, confirmed SARS-CoV-2 infection developed did not differ significantly from that in the placebo group, with risk reductions relative to placebo of 29.8% (95% confidence…”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 2-3 randomized controlled trial with rigorous design, clear reporting of demographics, and appropriate statistical methods. The main weaknesses are minor reporting gaps: the ethics approval details and informed consent are not fully described in the main text, and the data sharing statement is vague. A typographical error in Table 1 (543 (198) instead of 543 (19.8)) should be corrected.

This is an interventional clinical trial; both reviewers agreed on this classification. The evaluation covered all eight dimensions; species/strain, housing, and cell line criteria were not applicable. The statistics verification checked only 2 tests (both consistent), so the broader statistical analysis is not fully verified. The citation check found 1 reference not found in registry, which is a potential fabrication signal.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p = .170 · recomputed p = .117Reviewers 1, 2
Primary endpoint risk reduction for 5-day group
“risk reductions relative to placebo of 29.8% (95% confidence interval [CI], –16.7 to 57.8; P=0.17)”
Find in source
Taken as given: The risk reduction is 0.298 with 95% CI -0.167 to 0.578.; The CI is two-sided at 95%.; The p-value is two-tailed.
Method: Recomputed p-value from the estimate and 95% CI using the normal approximation.
How we recomputed it: pCI(0.298, -0.167, 0.578, 0)
CONSISTENTreported p = .120 · recomputed p = .061Reviewers 1, 2
Primary endpoint risk reduction for 10-day group
“risk reductions relative to placebo of 35.5% (95% CI, –11.5 to 62.7; P=0.12)”
Find in source
Taken as given: The risk reduction is 0.355 with 95% CI -0.115 to 0.627.; The CI is two-sided at 95%.; The p-value is two-tailed.
Method: Recomputed p-value from the estimate and 95% CI using the normal approximation.
How we recomputed it: pCI(0.355, -0.115, 0.627, 0)

lowinternal contradiction
In Table 1, the total for cigarette smoking is reported as 543 (198), which appears to be a typographical error; the percentage should be 19.8%.
“Cigarette smoking | 178 (19.3) | 189 (20.6) | 176 (19.6) | 543 (198)”
Table 1Find in source

Overstated conclusions

1 finding · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Treatment effect not shown to be clinically meaningfulAssessed

3 major claims checked against the paper's own evidence: all adequately supported.

supportedReviewers 1, 2
Postexposure prophylaxis with nirmatrelvir-ritonavir for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection.
The primary endpoint analysis shows no significant difference between treatment groups and placebo, with p-values of 0.17 and 0.12.
Evidence: Primary endpoint results: 2.6% vs 3.9% (5-day vs placebo), 2.4% vs 3.9% (10-day vs placebo), with risk reductions of 29.8% and 35.5% and p-values 0.17 and 0.12.
“postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection.”
AbstractFind in source
supportedReviewers 1, 2
The incidence of adverse events was similar across the trial groups.
Adverse event rates were 23.9%, 23.3%, and 21.7% across groups, which are similar.
Evidence: Table 3 shows adverse event rates of 23.9%, 23.3%, and 21.7% for the 5-day, 10-day, and placebo groups, respectively.
“The incidence of adverse events during the trial period was similar in the 5-day and 10-day nirmatrelvir–ritonavir groups and the placebo group (21.7 to 23.9% across trial groups)”
ResultsFind in source
supportedReviewers 1, 2
The trial was powered to detect a 70% reduction in risk.
The paper states this in the Discussion, and the observed risk reductions were smaller, explaining the lack of significance.
Evidence: Discussion states: 'The trial was powered to detect a 70% reduction in the risk of development of symptomatic, RT-PCR– or rapid antigen test–confirmed SARS-CoV-2 infection through day 14 relative to placebo.'
“The trial was powered to detect a 70% reduction in the risk of development of symptomatic, RT-PCR– or rapid antigen test–confirmed SARS-CoV-2 infection through day 14 relative to placebo”
DiscussionFind in source

Premise concern: effect size not shown to be clinically meaningful.

N/ASurrogate endpoint
The primary endpoint is a hard clinical outcome: development of symptomatic, RT-PCR- or rapid antigen test-confirmed SARS-CoV-2 infection through day 14. This is a clinical event, not a surrogate.
“The primary end point was the development of symptomatic SARS-CoV-2 infection, confirmed on reverse-transcriptase–polymerase-chain-reaction (RT-PCR) or rapid antigen testing, through day 14”
Find in source
INADEQUATEEffect size
The primary endpoint was not met; the observed risk reductions were not statistically significant (29.8% and 35.5% with P=0.17 and P=0.12, respectively). The effect size is not anchored to a clinically meaningful threshold and is not statistically supported.
“In each nirmatrelvir–ritonavir group, the percentage of participants in whom symptomatic, confirmed SARS-CoV-2 infection developed did not differ significantly from that in the placebo group, with risk reductions relative to placebo of 29.8% (95% confidence interval [CI], –16.7 to 57.8; P=0.17) in the 5-day nirmatrelvir–ritonavir group and 35.5% (95% CI, –11.5 to 62.7; P=0.12) in the 10-day nirmatrelvir–ritonavir group.”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior studies on household transmission rates, the ineffectiveness of existing prophylactic measures, and the failure of previous trials (e.g., molnupiravir) to show benefit. It also references the EPIC-HR trial for nirmatrelvir's efficacy in treatment. The rationale for the study is logically derived from these gaps. Limitations of prior research are implicitly addressed by the trial's design, though not explicitly discussed in the introduction.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on Covid-19 transmission, the lack of effective postexposure prophylaxis, and the mechanism of nirmatrelvir.

Evidence

“To date, clinical trials of Covid-19 treatments, including a phase 3 trial of molnupiravir, have not shown a significant benefit of postexposure prophylaxis.”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 2]

“Implementation of postexposure prophylactic treatment for household contacts of persons with SARS-CoV-2 infection, as recommended for other infectious diseases, may help prevent transmission and decrease the burden of Covid-19.”

absence[Introduction]

Limitations of prior research are not explicitly discussed in the introduction.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on Covid-19 transmission, the lack of effective postexposure prophylaxis, and the mechanism of nirmatrelvir, with a logical rationale for the study.

Evidence

“To date, clinical trials of Covid-19 treatments, including a phase 3 trial of molnupiravir, have not shown a significant benefit of postexposure prophylaxis.”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 2]

“Nirmatrelvir is a potent, selective SARS-CoV-2 main protease inhibitor. The Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients (EPIC-HR) trial involving patients at high risk for severe Covid-19 showed a reduced risk of severe disease progression”

absence[Introduction]

Limitations of prior research are not explicitly discussed as a separate section.

Randomization method is described as 1:1:1 ratio with stratification by risk factors and geographic region. Blinding is double-blind with matching placebo. The primary efficacy population is clearly defined. Power analysis is mentioned but details are relegated to the supplementary appendix. Inclusion/exclusion criteria are described. Outlier handling is not explicitly discussed, but the analysis population and missing data imputation for viral load are specified.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, blinding, and pre-specified analysis populations, though the power analysis is not fully detailed in the main text.

Evidence

“Randomization was stratified according to the presence of risk factors associated with severe Covid-19 and geographic region”

MethodsFind in source

“This phase 2–3, double-blind, randomized, placebo-controlled trial”

MethodsFind in source

paraphrase[Methods, Statistical Analysis]

“Sample-size calculations are provided in the Supplementary Appendix.”

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, and pre-specified analysis populations, though the power analysis is not fully detailed in the main text.

Evidence

“Randomization was stratified according to the presence of risk factors associated with severe Covid-19 and geographic region”

MethodsFind in source

“This phase 2–3, double-blind, randomized, placebo-controlled trial”

MethodsFind in source

paraphrase[Methods, Statistical Analysis]

“Sample-size calculations are provided in the Supplementary Appendix.”

Sex is reported for all participants. Age is reported as mean and median with ranges. Demographics include race/ethnicity and geographic region. Health status is captured via risk factors and serology status. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, race, and comorbidities, which are appropriate for a human trial.

Evidence

paraphrase[Table 1]

“Sex — no. (%) | Male | 419 (45.5) | 438 (47.8) | 424 (47.2) | 1281 (46.8)”

paraphrase[Table 1]

“Race or ethnic group — no. (%) | White | 714 (77.5) | 711 (77.5) | 704 (78.4) | 2129 (77.8)”

paraphrase[Table 1]

“Risk factors associated with severe Covid-19 — no. (%) | Yes | 675 (73.3) | 664 (72.4) | 647 (72.0) | 1986 (72.6)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, race, and comorbidities, which are appropriate for a human trial.

Evidence

paraphrase[Table 1]

“Sex — no. (%) | Male | 419 (45.5) | 438 (47.8) | 424 (47.2) | 1281 (46.8)”

paraphrase[Table 1]

“Risk factors associated with severe Covid-19 — no. (%) | Yes | 675 (73.3) | 664 (72.4) | 647 (72.0) | 1986 (72.6)”

The trial is registered at ClinicalTrials.gov (NCT05047601). The paper mentions ethical trial conduct in the supplementary appendix but does not name the approving ethics committee in the main text. Informed consent is implied but not explicitly described. Regulatory compliance is not explicitly stated in the main text.

Sub-criteria

iacuc statementN/A

informed consentINADEQUATE

irb ethics statementINADEQUATE

regulatory complianceINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The trial is registered and the paper states it was conducted ethically, but the specific IRB approval is not named in the main text.

Evidence

“ClinicalTrials.gov number, NCT05047601”

AbstractFind in source

paraphrase[Methods, Objectives, Participants, and Oversight]

“ethical trial conduct, and responsibilities related to the trial drugs are provided in the Supplementary Appendix.”

absence[Methods]

Informed consent is not explicitly described in the main text.

PASSReviewer 2· 85% conf

The trial is registered and the paper states it was conducted ethically, but the specific IRB approval is not named in the main text; however, the trial registration and protocol availability imply approval.

Evidence

“ethical trial conduct”

MethodsFind in source

“ClinicalTrials.gov number, NCT05047601”

AbstractFind in source

absence[Methods]

Informed consent is not explicitly described in the main text.

The drug is named with manufacturer (Pfizer) and dose (300 mg nirmatrelvir and 100 mg ritonavir). The placebo is described as matching capsules. Statistical software is not explicitly named in the main text, but the statistical methods are described. No antibodies, cell lines, or other biological reagents are used.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (nirmatrelvir-ritonavir) is clearly identified with dose and regimen, and the statistical software is identified.

Evidence

“receive 300 mg of nirmatrelvir and 100 mg of ritonavir for 5 days”

MethodsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not named in the main text.

PASSReviewer 2· 90% conf

The investigational product (nirmatrelvir-ritonavir) is clearly identified with dose and regimen, and the placebo is described; no other key biological resources are used.

Evidence

“receive 300 mg of nirmatrelvir and 100 mg of ritonavir for 5 days”

MethodsFind in source

“matching placebo capsules (consisting of inactive filler ingredients)”

MethodsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not identified in the main text.

The primary analysis uses a generalized estimating equation with compound symmetry to account for clustering. Risk reductions are reported with 95% CIs and exact p-values. The Hochberg method is used for multiplicity adjustment. Assumptions are not explicitly verified but the methods are standard. Data presentation includes per-group n and percentages. Mathematical plausibility checks are not applicable due to large N and continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedINADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported for primary and secondary endpoints.

Evidence

“A generalized estimating equation with compound symmetry variance–covariance structure was used to account for clustering.”

Statistical analysisFind in source

paraphrase[Results, Efficacy]

“P=0.17”

“risk reductions relative to placebo of 29.8% (95% confidence interval [CI], –16.7 to 57.8; P=0.17)”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported; the analysis accounts for clustering and multiplicity.

Evidence

“A generalized estimating equation with compound symmetry variance–covariance structure was used to account for clustering.”

Statistical analysisFind in source

paraphrase[Results, Efficacy]

“P=0.17”

“risk reductions relative to placebo of 29.8% (95% confidence interval [CI], –16.7 to 57.8; P=0.17)”

ResultsFind in source

The paper mentions a 'Data Sharing Statement' but does not provide details in the main text. No repository deposit or accession numbers are given. Code sharing is not applicable as no custom code is described.

Sub-criteria

code sharingN/A

accession numbersNOT REPORTED

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data sharing statement is mentioned but not detailed in the main text, and no repository or accession numbers are provided.

Evidence

“Data Sharing Statement A provided by the authors is available with the full text of this article at NEJM.org.”

End of paperFind in source

absence[Paper]

No repository deposit is mentioned.

WARNReviewer 2· 80% conf

A data sharing statement is mentioned but not detailed in the main text; no repository or accession numbers are provided, and code is not shared.

Evidence

“Data Sharing Statement A provided by the authors is available with the full text of this article at NEJM.org.”

End of paperFind in source

absence[Data Availability]

No repository deposit is mentioned.

The trial is registered (NCT05047601). Methods are detailed enough for replication. All outcomes are reported, including negative results. Limitations are discussed in the Discussion. Conclusions are proportional to the evidence. Funding and conflicts of interest are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent with trial registration, detailed methods, and discussion of limitations, though it does not reference a specific reporting guideline.

Evidence

“ClinicalTrials.gov number, NCT05047601”

AbstractFind in source

“Given the distinctive taste of nirmatrelvir–ritonavir, participants may have suspected that they were receiving active medication, which may have limited the effectiveness of the blinding.”

DiscussionFind in source

paraphrase[Footnotes]

“Supported by Pfizer.”

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional to the results.

Evidence

“ClinicalTrials.gov number, NCT05047601”

AbstractFind in source

“Given the distinctive taste of nirmatrelvir–ritonavir, participants may have suspected that they were receiving active medication, which may have limited the effectiveness of the blinding.”

DiscussionFind in source

paraphrase[Footnotes]

“Supported by Pfizer.”

Registered (4 IDs: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

ClinicalTrials.gov

ClinicalTrials.gov

ClinicalTrials.gov

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 31 references by DOI: 7 verified — 1 DOI unresolved, 23 no DOI (shown, not verified).

UNRESOLVED10.1016/s2214-109x(20
Concerns about bivalent COVID-19 vaccine and reasons for non-vaccination among adults who completed a primary series — Omnibus survey, March 10–April 30, 2023 & Household Pulse Survey, March 1–April 10, 2023
Cited DOI does not resolve to any Crossref record.
NO DOI
Contact settings and risk for transmission in 3410 close contacts of patients with Covid-19 in Guangzhou, China: a prospective cohort study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Contact tracing during coronavirus disease outbreak, South Korea, 2020
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Risk factors associated with COVID-19 infection: a retrospective cohort study based on contacts tracing
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
SARS-CoV-2 B.1.617.2 (delta) variant COVID-19 outbreak associated with a gymnastics facility — Oklahoma, April–May 2021
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
SARS-CoV-2 secondary attack rates in vaccinated and unvaccinated household contacts during replacement of delta with omicron variant, Spain
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
COVID-19 booster dose vaccination coverage and factors associated with booster vaccination among adults, United States, March 2022
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Update on community-acquired bacterial meningitis: guidance and challenges
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
FDA briefing document: drug name: nirmatrelvir tablets and ritonavir tablets copackaged for oral use
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Controlling the false discovery rate: a practical and powerful approach to multiple testing
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Coronavirus disease 2019 (COVID-19) treatment guidelines
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
FDA announces bebtelovimab is not currently authorized in any US region
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
FDA announces Evusheld is not currently authorized for emergency use in the U.S.
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Updated US infection- and vaccine-induced SARS-CoV-2 seroprevalence estimates based on blood donations, July 2020–December 2021
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A study to learn about the medicine called nirmatrelvir used in combination with ritonavir in people with weakened immune systems or at increased risk for poor outcomes who are hospitalized due to severe COVID-19 (EPIC-HOS)
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

4 data/code links checked; 4 live.

datahttp://clinicaltrials.gov/show/NCT05047601LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttp://clinicaltrials.gov/show/NCT05011513LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttp://clinicaltrials.gov/show/NCT04960202LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://www.clinicaltrials.gov/ct2/show/NCT05545319LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, grammar, clarity.

MINORconsistencyTable 1, footnote
“543 (198)”
→ 543 (19.8)
Percentage appears to be missing a decimal point.
MINORclarityMethods, Statistical Analysis
“A generalized estimating equation with compound symmetry variance–covariance structure was used to account for clustering.”
→ Clarify what clustering variable was used (e.g., household).
The clustering variable is not explicitly stated.
MINORgrammarDiscussion
“It is also important to consider whether the design of postexposure prophylaxis trials should address whether the treatment of the index patient reduces the incidence of household transmission.”
→ Consider rephrasing for clarity.
The sentence is awkwardly constructed.
MINORconsistencyTable 1, footnote
“Cigarette smoking | 178 (19.3) | 189 (20.6) | 176 (19.6) | 543 (198)”
→ The total percentage appears to be a typo; should be 19.8% (543/2736).
The percentage for the total column is likely a typographical error.
MINORgrammarDiscussion
“A particular strength of this trial is that it included participants from diverse age groups and geographical locations, a factor that enables broad generalizability of the results.”
→ Consider rephrasing to avoid a dangling modifier.
The sentence structure could be improved for clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically robust, but an informed reader should weigh the minor reporting gaps in ethics and data sharing, and the typographical error in Table 1. The unresolved reference in the bibliography warrants verification. No major validity threats were identified, but a correction or erratum for the Table 1 typo and a clarification of the data sharing mechanism would strengthen the record.

1.
HIGHcopyedit
Correct the typographical error in Table 1 footnote: change '543 (198)' to '543 (19.8)' for the cigarette smoking total percentage.
The percentage is mathematically impossible as written and could be misread as a data error.
2.
HIGHethics
In the Methods section, explicitly name the institutional review board or ethics committee that approved the trial and include the approval/protocol number.
The main text currently only mentions ethical conduct in the supplementary appendix, which is insufficient for transparency.
3.
HIGHethics
In the Methods section, explicitly describe the informed consent process (e.g., written informed consent obtained from all participants).
Informed consent is a fundamental ethical requirement and is not currently described in the main text.
4.
HIGHdata code
In the Data Availability section, provide a concrete data access mechanism, such as a managed-access platform or data-sharing committee, with conditions and timeframe.
The current statement is vague and does not allow readers to know how to request data.
5.
HIGHother
Verify or correct the reference 'Concerns about bivalent COVID-19 vaccine and reasons for non-vaccination among adults who completed a primary series — Omnibus survey, March 10–April 30, 2023 & Household Pulse Survey, March 1–April 10, 2023' (DOI 10.1016/s2214-109x(20) which was not found in the registry.
A reference that cannot be found in any registry may be fabricated or contain an incorrect DOI, which is a serious integrity concern.
6.
MEDIUMstatistics
In the Methods, Statistical Analysis section, explicitly state the clustering variable used in the GEE (e.g., household).
The copyedit flagged that the clustering variable is not stated, which is important for understanding the analysis.
7.
MEDIUMstatistics
In the Methods, identify the statistical software used (e.g., SAS version 9.4) to improve reproducibility.
Naming the software is a standard reproducibility requirement and is currently missing.
8.
MEDIUMreporting
In the Methods, provide the full sample-size calculation details, including assumed event rates, power, and alpha, in the main text or clearly reference the supplementary appendix.
Readers need these details to assess the trial's sensitivity and power.
9.
MEDIUMreporting
In the Discussion, explicitly state adherence to CONSORT reporting guidelines.
Explicitly referencing the guideline enhances transparency and demonstrates compliance.
10.
MEDIUMreporting
In the Methods, describe the blinding procedures in more detail, including who was blinded and how allocation concealment was maintained.
The current description is brief and could be strengthened for reproducibility.
11.
MEDIUMreporting
In the Methods, explicitly state how outliers were handled in the analysis, or note that no outliers were excluded.
Outlier handling is a common reviewer concern and is currently not addressed.
12.
LOWcopyedit
Rephrase the awkward sentence in the Discussion: 'It is also important to consider whether the design of postexposure prophylaxis trials should address whether the treatment of the index patient reduces the incidence of household transmission.'
The sentence is grammatically awkward and could be clearer.
13.
LOWcopyedit
Rephrase the sentence in the Discussion to avoid a dangling modifier: 'A particular strength of this trial is that it included participants from diverse age groups and geographical locations, a factor that enables broad generalizability of the results.'
The sentence structure could be improved for clarity.

Full text (37,232 chars)Analyzed: Aug 16, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.

Hammond J, Yunis C, Fountaine RJ, Luscan G, Burr AM, Zhang W, Wisemandle W, Soares H, Baniecki ML, Hendrick VM, Kalfov V, Pypstra R, Rusnak JM

DOI

10.1056/NEJMoa2309002

Record issued

2026-08-16

Engine

7.39.0

Exported

2026-09-22